TABLE 2

Effect of Various Clinical, Radiologic, and Histologic Findings on Progression-Free Survival in 44 Patients with Endocrine Tumors

	Univariate			Multivariate
Parameter	HR	95% CI	P	HR	95% CI	P
Sex (male vs. female)	1.01	0.39–2.61	0.979	—	—	—
Site of primary tumor			0.458
Gastrointestinal vs. pancreas	1.39	0.52–3.70	0.513	—	—	—
Lung vs. pancreas	2.32	0.61–8.84	0.219	—	—	—
Syndrome (no vs. yes)	0.78	0.30–2.08	0.625	—	—	—
MEN 1 (no vs. yes)	6.15	0.80–47.5	0.082	—	—	—
Stage of disease at CT^*	1.63	0.62–4.25	0.321	4.12	0.99–17.2	0.052
Tumor differentiation (poorly vs. well)	5.31	1.86–15.2	0.002	7.00	2.11–23.3	0.001
Ki67 (≤5 vs. >5)	1.35	0.44–4.14	0.602	NA	NA	NA
SUVmax (≤17.6 vs. ≥19.3)	5.97	2.22–16.1	<0.001	9.56	2.87–31.8	<0.001
Therapy (SST vs. SST + SSTRT)^†	3.81	1.36–10.7	0.011	3.82	1.25–11.7	0.019

↵* Risk associated with increase in 1 category.
↵† One patient without therapy was excluded.
HR = hazard ratio; MEN 1 = multiple endocrine neoplasia type 1; NA = not applicable; SST = somatostatin analogs; SSTRT = radiolabeled somatostatin analogs.